Nabriva Therapeutics AG (NASDAQ:NBRV) Director Sells $15,840.60 in Stock

Nabriva Therapeutics AG (NASDAQ:NBRV) Director George Harrison Talbot sold 170 shares of the stock in a transaction dated Monday, June 19th. The stock was sold at an average price of $93.18, for a total value of $15,840.60. Following the transaction, the director now owns 3,249 shares in the company, valued at $302,741.82. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

George Harrison Talbot also recently made the following trade(s):

  • On Tuesday, May 30th, George Harrison Talbot sold 210 shares of Nabriva Therapeutics AG stock. The stock was sold at an average price of $101.26, for a total value of $21,264.60.
  • On Thursday, May 25th, George Harrison Talbot sold 325 shares of Nabriva Therapeutics AG stock. The stock was sold at an average price of $100.56, for a total value of $32,682.00.
  • On Monday, May 15th, George Harrison Talbot sold 50 shares of Nabriva Therapeutics AG stock. The shares were sold at an average price of $101.50, for a total value of $5,075.00.
  • On Tuesday, May 16th, George Harrison Talbot sold 200 shares of Nabriva Therapeutics AG stock. The shares were sold at an average price of $102.44, for a total value of $20,488.00.

Shares of Nabriva Therapeutics AG (NASDAQ NBRV) traded up 1.90% during trading on Wednesday, hitting $10.75. 600 shares of the stock were exchanged. Nabriva Therapeutics AG has a 52 week low of $3.52 and a 52 week high of $12.75. The firm’s market capitalization is $29.25 million. The stock’s 50 day moving average price is $9.87 and its 200 day moving average price is $9.52.

COPYRIGHT VIOLATION NOTICE: “Nabriva Therapeutics AG (NASDAQ:NBRV) Director Sells $15,840.60 in Stock” was posted by BBNS and is owned by of BBNS. If you are viewing this report on another publication, it was illegally stolen and republished in violation of United States & international copyright laws. The original version of this report can be viewed at https://baseballnewssource.com/markets/insider-selling-nabriva-therapeutics-ag-nbrv-director-sells-15840-60-in-stock-updated-updated/1072418.html.

Several equities research analysts have recently weighed in on the company. Cantor Fitzgerald set a $16.00 price objective on Nabriva Therapeutics AG and gave the company a “buy” rating in a research note on Tuesday. Zacks Investment Research raised Nabriva Therapeutics AG from a “hold” rating to a “buy” rating and set a $11.00 target price on the stock in a report on Saturday, May 27th. HC Wainwright reiterated a “buy” rating and set a $16.00 target price on shares of Nabriva Therapeutics AG in a research report on Friday, June 30th. ValuEngine upgraded shares of Nabriva Therapeutics AG from a “sell” rating to a “hold” rating in a research report on Saturday, June 24th. Finally, Wedbush reiterated an “outperform” rating and set a $13.00 target price on shares of Nabriva Therapeutics AG in a report on Monday, May 15th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Nabriva Therapeutics AG presently has a consensus rating of “Buy” and an average price target of $15.29.

Several institutional investors have recently bought and sold shares of NBRV. Renaissance Technologies LLC acquired a new stake in shares of Nabriva Therapeutics AG during the fourth quarter valued at $103,000. Almanack Investment Partners LLC. acquired a new stake in shares of Nabriva Therapeutics AG during the first quarter valued at $1,870,000. Nationwide Fund Advisors acquired a new stake in shares of Nabriva Therapeutics AG during the first quarter valued at $2,074,000. Orbimed Advisors LLC boosted its stake in shares of Nabriva Therapeutics AG by 27.6% in the fourth quarter. Orbimed Advisors LLC now owns 1,677,940 shares of the biotechnology company’s stock valued at $10,001,000 after buying an additional 362,940 shares in the last quarter. Finally, Vivo Capital LLC boosted its stake in shares of Nabriva Therapeutics AG by 27.6% in the fourth quarter. Vivo Capital LLC now owns 4,021,559 shares of the biotechnology company’s stock valued at $23,968,000 after buying an additional 869,859 shares in the last quarter. 56.73% of the stock is currently owned by institutional investors.

About Nabriva Therapeutics AG

Nabriva Therapeutics AG is an Austria-based clinical-stage biopharmaceutical company engaged in the research and development of antibiotics to treat infections. Its lead product candidate, lefamulin, is a pleuromutilin antibiotic for systemic administration in humans. The Company develops both intravenous (IV) and oral formulations of lefamulin for the treatment of community-acquired bacterial pneumonia (CABP).

Insider Buying and Selling by Quarter for Nabriva Therapeutics AG (NASDAQ:NBRV)

Receive News & Ratings for Nabriva Therapeutics AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics AG and related companies with our FREE daily email newsletter.

 


Latest News

Michael Jordan and Derek Jeter May Buy Miami Marlins
Michael Jordan and Derek Jeter May Buy Miami Marlins
First Half Favorites for MLB Awards
First Half Favorites for MLB Awards
Houston’s George Springer Proving He Has What it Takes
Houston’s George Springer Proving He Has What it Takes
Aaron Judge Passes Yankees Legend Joe DiMaggio for Rookie Home Runs
Aaron Judge Passes Yankees Legend Joe DiMaggio for Rookie Home Runs
Legends from Latin American Will Be Honored by MLB
Legends from Latin American Will Be Honored by MLB
Home Run Derby Expected to Be the Best Yet
Home Run Derby Expected to Be the Best Yet


Leave a Reply

 
© 2006-2017 BBNS.